Home 2017-05-08T02:45:42+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Read more

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

Read more

prescient therapeutics

LATEST NEWS

05/10/2017Investor Presentation - October 2017PDF
03/10/2017PTX-100 to Re-enter Trials in Hematology NichePDF
04/09/2017Prescient to resume AML trialPDF
29/08/2017Appendix 4G and Corporate Governance StatementPDF
29/08/2017Appendix 4E and 2017 Annual ReportPDF
01/08/2017Investor Newsletter - August 2017PDF